Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence - Abstract

Department of Medicine, Sections of Hematology/Oncology, University of Chicago, Chicago, Illinois, USA.


Uncovering the dominant molecular deregulation among the multitude of pathways implicated in aggressive prostate cancer is essential to intelligently developing targeted therapies. Paradoxically, published prostate cancer gene expression signatures of poor prognosis share little overlap and thus do not reveal shared mechanisms. The authors hypothesize that, by analyzing gene signatures with quantitative models of protein-protein interactions, key pathways will be elucidated and shown to be shared.

The authors statistically prioritized common interactors between established cancer genes and genes from each prostate cancer signature of poor prognosis independently via a previously validated single protein analysis of network (SPAN) methodology. Additionally, they computationally identified pathways among the aggregated interactors across signatures and validated them using a similarity metric and patient survival.

Using an information-theoretic metric, the authors assessed the mechanistic similarity of the interactor signature. Its prognostic ability was assessed in an independent cohort of 198 patients with high-Gleason prostate cancer using Kaplan-Meier analysis.

Of the 13 prostate cancer signatures that were evaluated, eight interacted significantly with established cancer genes (false discovery rate < 5%) and generated a 42-gene interactor signature that showed the highest mechanistic similarity (p< 0.0001). Via parameter-free unsupervised classification, the interactor signature dichotomized the independent prostate cancer cohort with a significant survival difference (p=0.009). Interpretation of the network not only recapitulated phosphatidylinositol-3 kinase/NF-κB signaling, but also highlighted less well established relevant pathways such as the Janus kinase 2 cascade.

SPAN methodolgy provides a robust means of abstracting disparate prostate cancer gene expression signatures into clinically useful, prioritized pathways as well as useful mechanistic pathways.

Written by:
Chen JL, Li J, Stadler WM, Lussier YA.   Are you the author?

Reference: J Am Med Inform Assoc. 2011 Jul 1;18(4):392-402.
doi: 10.1136/amiajnl-2011-000178

PubMed Abstract
PMID: 21672909 Prostate Cancer Section



email news signup